Dr. Obradovic's group focuses on leveraging novel approaches for analysis of transcriptional, TCR-Seq, and spatial data across clinical and pre-clinical data toward improved understanding of the immune mechanisms of resistance to checkpoint-inhibitor immunotherapies, with projects aimed at inferring and prioritizing synergistic combination-therapies and regulatory targets for re-programming immune micro-environment (T-cells, macrophages, fibroblasts) toward an anti-tumor phenotype. Within the Biohub NY "Immune Cell Re-Programming" group, this role requires experience in research settings, a background in biology, and a proven ability to design, evaluate, and publish innovative computational methodologies that leverage machine learning, statistics, and multi-omics to advance biological research and discovery.